Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550221 | 0.80 | ACHE (0.63) | BCHEHTR2BCYP3A4ACHE | |
| SCHEMBL1114944 | 0.80 | ACHE (0.63) | BCHEHTR2BCYP3A4ACHE | |
| Hydrochloric Acid SCHEMBL4833887 | 0.79 | ACHE (0.61) | BCHEHTR2BCYP3A4ACHE | |
| SCHEMBL28409784 | 0.79 | ACHE (0.61) | BCHEHTR2BCYP3A4ACHE | |
| Acetic Acid SCHEMBL27493902 | 0.75 | ACHE (0.60) | BCHEHTR2BCYP3A4ACHE | |
| Acetic Acid SCHEMBL29374009 | 0.75 | ACHE (0.60) | BCHEHTR2BCYP3A4ACHE | |
| SCHEMBL3149281 | 0.74 | ALDH1A1 (0.49) | BCHEALDH1A1CYP2D6CYP2C9ALOX15 | |
| SCHEMBL14156625 | 0.74 | ACHE (0.54) | BCHEHTR2BCYP3A4ACHE | |
| SCHEMBL8267415 | 0.73 | ACHE (0.61) | TDP1HTR2CHTR2AHTR2BCYP3A4 | |
| SCHEMBL9636847 | 0.73 | GBA1 (0.50) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954676-B1 | PROCESS FOR MAKING DONEPEZIL | SYNTHON BV (NL) | 2012-11-07 | — | — | EP | disclosed |
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | RICHTER GEDEON NYRT. (HU) | 2008-12-11 | — | — | US | disclosed |
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | RICHTER GEDEON NYRT. (HU) | 2008-12-11 | — | — | US | disclosed |
| US-20070135644-A1 | PROCESS FOR MAKING DONEPEZIL | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| US-20070135644-A1 | PROCESS FOR MAKING DONEPEZIL | SYNTHON BV (NL) | 2007-06-14 | — | — | US | disclosed |
| WO-2007057226-A2 | PROCESS FOR MAKING DONEPEZIL | SYNTHON B.V. (NL) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306271-A1 | Novel Process for Production of Highly Pure Polymorph (I) Donepezil Hydrochloride | DRD4, IDO1, ADH1A | BCHE 20/4885ALDH1A1 322/4885CYP2D6 69/4885 |
| US-20070135644-A1 | PROCESS FOR MAKING DONEPEZIL | MAOA, ACHE, CHAT | BCHE 4/4885ALDH1A1 882/4885CYP2D6 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.